Table 1. Baseline characteristics.
| Characteristics | Ph alone (N=34) | Ph plus ACAs (N=118) | Overall (N=152) |
|---|---|---|---|
|
| |||
| Median age, years (range) | 54 (26-80) | 55 (19-85) | 55 (19-85) |
|
| |||
| Median WBC, × 109/L (range) | 14.7 (0.9-243.6) | 8.3 (0.3-232.3) | 9.5 (0.3-243.6) |
|
| |||
| Performance status, n (%) | |||
| 0-1 | 28 (82) | 102 (86) | 130 (86) |
| 2 | 4 (12) | 9 (8) | 15 (10) |
| Unknown | 2 (6) | 5 (4) | 7 (5) |
|
| |||
| CD20 expression ≥20%, n/N (%) | 10/30 (33) | 55/110 (50) | 65/140 (46) |
|
| |||
| CNS leukemia, n/N (%) | 3/34 (9) | 18/117 (15) | 21/151 (14) |
|
| |||
| BCR-ABL transcript, n (%) | |||
| e1a2 or e1a3 (p190) | 17 (52) | 92 (78) | 109 (72) |
| e13a2 or e14a2 (p210) | 16 (48) | 26 (22) | 42 (28) |
|
| |||
| TKI | |||
| Imatinib | 7 (21) | 29 (25) | 36 (24) |
| Dasatinib | 18 (53) | 56 (47) | 74 (49) |
| Ponatinib | 9 (26) | 33 (28) | 42 (28) |
Ph, Philadelphia chromosome; ACAs, additional chromosomal abnormalities; WBC, white blood cell; CNS, central nervous system; TKI, tyrosine kinase inhibitor